The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
|Videos|November 7, 2016
Dr. Concepcion on the Use of Eligard in Prostate Cancer Treatment
Author(s)Raoul Concepcion, MD
Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.
Advertisement
Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.
Eligard, manufactured by Tolmar, is an LHRH agonist which overdrives the testical for a brief period of time, resulting in a castration level of testosterone.
What makes Eligard unique is its delivery system, Concepcion says. Eligard's Atrigel delivery system is a slow release, which results in lower, sustained levels of testosterone.
Advertisement
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.
No efficacy benefit was found in adding SBRT to dual checkpoint blockade, though a subset of patients responded to nivolumab plus ipilimumab.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Sequencing, Access, and Eligibility Drive CAR T-Cell Therapy Decisions in Early Relapse Myeloma
2
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
3
FDA Grants Fast Track Designation to SYS6090 in Pretreated MSS/pMMR mCRC
4
UT MD Anderson Honors Visionary Leadership of Peter Pisters, MD, MHCM, Following Retirement Announcement; Shares Transition Plans
5